GlassScriptPhysician profile
Morgan Pegg
NPI 1689324477
$3,752.23
in general payments reported to CMS, 2019-2025
23 companies · $2,864 in 2025
The $2,864 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $889 · 2025: $2,864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,605 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,605.25 |
| Education | $146.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,746.91 | 2024-2025 | |
| Glaxosmithkline, LLC. | $322.97 | 2025 | Benlysta |
| Abbvie INC. | $275.41 | 2025 | |
| Amgen INC. | $225.81 | 2024-2025 | Tavneos, Otezla, Krystexxa |
| Janssen Biotech, INC. | $205.30 | 2025 | Tremfya |
| Abiomed | $150.00 | 2025 | |
| Mallinckrodt Hospital Products INC. | $146.62 | 2025 | Acthar |
| Inari Medical, INC. | $129.26 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Ucb, INC. | $100.56 | 2024-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $74.85 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $71.67 | 2024-2025 | Saphnelo |
| Sanofi-Aventis U.S. LLC | $69.99 | 2024 | |
| Sobi, INC | $31.20 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.76 | 2025 | Cuvitru |
| Medtronic, INC. | $23.81 | 2025 | Micra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $22.68 | 2025 | Zepbound, Taltz |
| E.R. Squibb & Sons, L.L.C. | $22.56 | 2025 | Orencia |
| Bayer Healthcare Pharmaceuticals INC. | $19.89 | 2024 | |
| Radius Health, INC. | $18.45 | 2025 | Tymlos |
| Ani Pharmaceuticals, INC. | $17.90 | 2025 | Sovuna |
| Insmed, INC. | $17.02 | 2025 | Brinsupri, Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.97 | 2025 | Spevigo |
| Novo Nordisk INC | $14.64 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Pegg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.